|
THIRD ROUND OF MALARIA ADVOCACY INNOVATION GRANTS (AFRICA AND ASIA)
Malaria Consortium is now accepting applications for its Malaria Advocacy Innovation Grants. Applications are invited from African and Asian community based organisations, non-governmental organisations, media organisations/institutions, and individuals (within institutions/sponsored by organisations only) who are actively working towards engaging civil society actors and the public through innovative activities such as advocacy campaigns, forums, networks, music, art, film or media related projects. Deadline to submit proposals is Monday 16 June 2008.
The application form is available English at www.mobilising4malaria.org and http://www.ethiopia.coalitionagainstmalaria.org/
TROISIĖME SĒRIES DE SUBVENTIONS POUR INNOVATIONS DANS LE PLAIDOYER CONTRE LE PALUDISME
Malaria Consortium reçoit actuellement les candidatures pour des Subventions pour Innovations dans le Plaidoyer contre le Paludisme. Les demandes sont invitées de la part des organisations communautaires, non-gouvernementales, des médias, et des individus (au sein d’institutions ou sponsorisés par une organisation) en Afrique et en Asie, s’engageant dans la mise en place d’activités innovantes destinées à accroître l’implication de la société civile et de l’opinion publique par exemple au travers de campagnes d’information, de forums, de réseaux, ou de projets musicaux, artistiques, cinématographiques ou médiatiques, seront acceptées.
Les candidatures doivent être remises au plus tard avant le lundi 16 juin 2008.
Le formulaire à remplir est disponible à www.mobilising4malaria.org et http://cameroon-fr.coalitionagainstmalaria.org/
Delphine Valette
International Advocacy Coordinator
Malaria Consortium Worldwide
Tel:+ 44 (0)20 7549 0218 (Direct line)
+ 44 (0)20 7549 0210
Fax:+ 44 (0)20 7549 0211
European Malaria Vaccine Development Association
Call for Proposals
Call for Selecting New Potential Malaria Vaccine Candidates and the Developing Institutions to Enter into EMVDA
Grant scheme |
Antigen Portfolio |
Disease |
Malaria |
Call identifier |
LSHP-CT-2006-037506 |
Open for application |
31 March 2008 |
Deadline for application |
5 May 2008 |
The purpose of the present call is to invite the scientific community to submit a proposal on the clinical testing of a malaria blood stage candidate vaccine. Institutions developing selected candidates will enter into the EMVDA programme, and be encouraged to enter the preclinical comparative platform. As part of the EMVDA programme institutions will be eligible to respond to an internal call for GMP production and phase 1 clinical trials. Further information on the call and procedures can be found at http://www.emvi.org/emvda+home/calls.
Development of Novel Interventions and Tools for the Control of Malaria, Neglected Tropical Diseases and their Vectors (R01)
Call for Applications by NIH
Key Dates
Release/Posted Date: March 7, 2008
Opening Date: June 10, 2008 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): June 10, 2008
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Due Date(s): July 10, 2008
Peer Review Date(s): November, 2008
Council Review Date(s): January 2009
Earliest Anticipated Start Date(s): May 2009
Additional Information To Be Available Date (Activation Date): Not Applicable
Expiration Date: July 11, 2008
More information about this grant opportunity is found here:http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-08-005.html
EMVI 2007 Call for Proposals: Development and Clinical Testing of Candidate Molecules Towards Experimental P. falciparum Malaria Vaccines
Deadline for submission: Friday 23 November 2007, 17:00 hours
Download Application Form
EMVI’s mission is
To contribute to the global efforts to control malaria by:
- Providing a mechanism for accelerated development of malaria vaccines in Europe and Developing Countries.
- Promoting affordability and accessibility of malaria vaccines in Developing Countries.
EMVI shall contribute to the post validation phase of nationally and internationally funded malaria vaccine research and development, and facilitate the process that takes experimental malaria vaccines through to limited GMP production and clinical trials. EMVI will not support antigen discovery studies.
European and Developing country research groups are invited to submit full proposals for the continued development and clinical testing of candidate molecules towards experimental P. falciparum malaria vaccines.
EMVI may support work, which will move potential candidates into the clinical trials phase, including late stage pre-clinical studies in non-human primates, formulation, process development, GMP production, toxicology and clinical trials
Any proposals will be considered, including those addressing the potential for immediate or future combinations of two or more components. (For definition of combination vaccines and reflection on the many challenges facing development of combination vaccines, please refer to EMVI’s web site http://www.emvi.org/meeting+reports.
EMVI’s Scientific Advisory Committee (SAC) of independent scientists, - please refer to http://www.emvi.org assisted by other experts as the need arises, will review the proposals.
EMVI actively collaborates with among others the international malaria vaccine funders mentioned on the website www.emvi.org, and is a partner in the European and Developing Countries Clinical Trials Partnership (EDCTP).
In elaborating a proposal you are advised to address the following key issues systematically.
1) Epidemiology:
- What is known and what information is lacking?
- Are epidemiological studies needed for the development of the vaccine?
- If known, what is (are) the hypothetical or assumed correlate(s) of protection or immunity in target populations?
2) Scientific rationale:
a) Background:
- Target populations: age, geographical zones, special risk groups. Are there genetic (haplotype)differences in populations that do better than others, immunologically and clinically?
b) Antigen choice; stage specific or multistage, pros and cons
- Single or multiple antigens
- Is it known the antigen an essential gene?
- Document genetic variability?
- Any homology with human proteins?
- What is the immune response to this (these) antigen(s) in naturally exposed populations?
- Are certain immune responses correlated to better clinical outcomes?
- What are the theoretical/hypothetical reasons why an immune-response to this (these) tigen(s)would be detrimental to the parasite?
- Are there in-vivo or in-vitro tests to support this?
- Expected performance of the vaccine.
- What would the investigator consider the best proof of concept test that could be designed?
c) Choice of vector/formulation/antigen-presentation/expression system
- Does the investigator know what type of immune-response needs to be induced?
- Has an antigen delivery system that achieves the required response been identified?
- Is this system validated in humans? in animals? as a viable option for wide spread/scale-up and use? Discuss advantages and limitations
- Competing products: Other vaccines, other available products
d) Preclinical development:
- Correlates of protection; development of immunological tests for the assessment of the quality of the immune response; animal models
e) Route of administration:
- Is there any data to support alternative routes of administration of interest for the antigen?
f) Summary of clinical development to date, if any
3) Vaccine production:
- What are the plans for process development/manufacturing?
- Is an adjuvant needed?
- What reagents will have to be developed to control product and its immunogenicity?
- What assays need to be developed or validated prior to initiating clinical trials?
- Quality control studies:
- Animal studies including pharmaco-toxicological studies
- Stability studies
- Potency assay
- Are the tests already developed? Are there already any product characteristics and product specifications available?
4) Clinical development strategy:
· Describe the intended clinical development strategy, including primary and secondary clinical endpoints, which will result in a clear decision to proceed to development with a well-defined product and with reasonable probability of success.
- Define the rationale for phase 1 - 2a studies.
- Are there pivotal studies that would form the basis for GO/NO-GO decisions?
- Define hypothesis, objectives, main outcome measurement, study design and time-lines.
The proposal-text should not exceed 25 (twenty-five) pages. The operational plans should be explained in work packages. The number of work packages should not exceed 6 (six). Elaboration of ethical aspects and the benefits for target populations is also required.
The proposal does not need to be anonymous, and relevant literature should be referred to in the text and a list of references should be provided as the ultimate page(s) in the Application Form (Click link to download).
Manuscripts submitted, but not yet published, can be attached, and essential research results not yet ready for submission can be submitted together with the proposal in a format, which describes and discusses the results, strictly to substantiate the proposal. Relevant reprints can be annexed.
The penultimate page of the proposal should be a budget outline relating to each work package.
Proposals will be dealt with in confidence. They should be e-mailed to:
Dr. Odile Leroy
Executive Director, EMVI
C/O Statens Serum Institut
Artillerivej 5
DK-2300 Copenhagen S
Denmark
e-mail: oly@ssi.dk with a copy to:
Dr. Babatunde Imoukhuede
Director of Clinical and Regulatory Affairs, EMVI
12 Bell House, Ewen Crescent
Tulse Hill
London SW2 2PW
United Kingdom
e-mail: ebi@ssi.dk
and
Professor Nils Strandberg Pedersen
CEO
C/O Statens Serum Institut
Artillerivej 5
DK-2300 Copenhagen S
Denmark
e-mail: nsp@ssi.dk
Additional information is available from Dr. Odile Leroy or Dr Babatunde Imoukhuede.
A decision will be communicated to applicants by mid February 2008.
Call for Applications for the Award of Research Training Grants - 2008
The UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) invites applications for the award of Research Training Grants (RTG) from individuals who are nationals of, and employed in, least developed disease endemic countries (LDC) and developing disease endemic countries (DEC) with lesser developed research capacities. RTGs are awarded, on a competitive basis, for studies leading to a postgraduate degree, or for acquiring specialized skills. Studies must be on one or more of the TDR target diseases - malaria, leishmaniasis, schistosomiasis, lymphatic filariasis and onchocerciasis, African trypanosomiasis and Chagas disease, leprosy, dengue and tuberculosis, in laboratory, clinical, applied field research and social sciences disciplines, relevant to TDR and/or national priorities.
All applications must be received by 15 November 2007
Further information please go to the website : http://www.who.int/tdr/grants/grants/
and please contact Mr. Steven Wayling (waylings@who.int)
Call for applications for Career Development Fellowships and sabbatical opportunities for knowledge management and translation in infectious diseases of poverty in the framework of the TropIKA.net initiative
All applications must be received by 15 October 2007
Further information please go to the website : http://www.who.int/tdr/grants/grants
and please contact:
Attention Edith Certain
Special Programme for Research and Training in Tropical Diseases
World Health Organization, 1211 Geneva 27, Switzerland
Telephone: +41-22-791-2061 Fax: +41-22-791-4854
E-mail: tdrstewardship@who.int
Current calls for application EDCTP: www.edctp.org
|
